HEAD AND NECK SQUAMOUS CELL CARCINOMA

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control

Last updated Jul 02, 2026 00:00 UTC

New drug ALE.P02 targets tough cancers in early trial

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control

Last updated Jul 01, 2026 00:00 UTC

New cancer drug YL211 enters first human tests

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control

Last updated Jul 01, 2026 00:00 UTC

New drug XTX301 takes on advanced cancers in first human trial

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control

Last updated Jun 27, 2026 14:03 UTC

New hope for Hard-to-Treat cancers? early trial launches

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC

New hope for Hard-to-Treat cancers: first human trial launches

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC

MRNA vaccine technology takes on advanced cancers

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC

New combo attack: immunotherapy plus chemo before surgery for head and neck cancer

This phase 2 trial tests whether giving the immunotherapy drug pembrolizumab along with chemotherapy before surgery, followed by pembrolizumab alone for about a year after surgery, can improve outcomes for people with recurrent head and neck cancer. The study aims to see if this …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC

New combo therapy aims to shrink head and neck tumors

This phase 2 study tests whether adding the experimental drug VS-101 to standard chemoradiotherapy helps shrink tumors in 30 adults with head and neck cancer. Participants are randomly assigned to receive VS-101 plus chemoradiation or chemoradiation alone. The main goal is to see…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: VSPharmTech Co.,Ltd. • Aim: Disease control

Last updated Jun 27, 2026 14:01 UTC

New Antibody-Drug conjugate targets Hard-to-Treat cancers

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

Can a gene test guide better treatment for head and neck cancer survivors?

This study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

New drug IDE034 targets Hard-to-Treat cancers in early trial

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

New triple-drug cocktail takes on hard-to-treat head and neck cancer

This phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control

Last updated Jun 27, 2026 13:08 UTC

New drug YH32364 targets Hard-to-Treat cancers in first human trial

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control

Last updated Jun 27, 2026 13:08 UTC

Engineered immune cells take aim at Hard-to-Treat cancers

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

New immune drug AZD6750 targets Hard-to-Treat cancers

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

New drug combo aims to outsmart Hard-to-Treat cancers

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

New antibody EPI-326 enters first human trials for tough cancers

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control

Last updated Jun 27, 2026 13:06 UTC

New vaccine shows promise in early trial for tough cancers

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control

Last updated Jun 27, 2026 13:04 UTC

New cancer drug combo trial launches for Hard-to-Treat tumors

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Calico Life Sciences LLC • Aim: Disease control

Last updated Jun 27, 2026 13:03 UTC

New drug JNJ-95437446 enters human testing for Hard-to-Treat cancers

This early-stage trial tests a new drug called JNJ-95437446 in people with advanced solid tumors, including colorectal cancer, that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking safety more closely in a larger…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control

Last updated Jun 27, 2026 13:03 UTC

New STING agonist drug enters human trials for Hard-to-Treat cancers

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 13:02 UTC

New hope for head and neck cancer: experimental drug petosemtamab enters final testing

This Phase 3 trial tests a new drug called petosemtamab against standard treatments (cetuximab, methotrexate, or docetaxel) in 600 adults with advanced head and neck cancer that has spread or come back. Participants must have already tried immunotherapy and chemotherapy. The main…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Jun 27, 2026 13:01 UTC

Could a Two-Drug punch before surgery shrink head & neck tumors?

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

New combo therapy aims to boost survival in head and neck cancer

This study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer. About 700 adults with PD-L1 positive cancer that has spread or come back will receive either the combination or pembrolizumab alon…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

New drug hope for patients with advanced cancers

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

New drug duo aims to shrink hard-to-treat tumors

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Biocity Biopharmaceutics Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 12:38 UTC

New immunotherapy combo shows promise for tough cancers

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 27, 2026 12:38 UTC

New cancer drug KK2260 enters first human tests

This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. Ab…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 12:38 UTC

New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients

This study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Res…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Disease control

Last updated Jun 27, 2026 12:37 UTC

Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 27, 2026 12:37 UTC

New drug targets Hard-to-Treat cancers with genetic weakness

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:37 UTC

New cocktail aims to shrink head and neck tumors before surgery

This phase II trial tests whether adding the targeted drug nimotuzumab to immunotherapy and chemotherapy before surgery can improve outcomes for people with locally advanced head and neck cancer. About 182 participants will receive the combination or standard treatment. The main …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control

Last updated Jun 27, 2026 12:37 UTC

New hope for advanced cancer: combo therapy trial launches

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:37 UTC

Supercharged immune cells take on hard-to-treat cancers

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 12:35 UTC

New hope for tough cancers? early trial launches for ABBV-711

This early-phase study tests an experimental drug called ABBV-711, alone or with another drug (budigalimab), in adults with advanced squamous tumors (like certain lung or head and neck cancers). The main goals are to check safety and see if the tumors shrink. About 220 people wil…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control

Last updated Jun 27, 2026 12:35 UTC

New combo therapy aims to fight HPV head and neck cancer

This phase 2 pilot study is testing a new drug called CUE-101, alone or combined with pembrolizumab, in 30 people with newly diagnosed, locally advanced HPV-16 head and neck cancer. The goal is to see if the combination boosts the immune system's ability to fight the cancer befor…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control

Last updated Jun 27, 2026 12:34 UTC

New drug combo shows promise for Hard-to-Treat cancers

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: GI Innovation, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:34 UTC

New cancer drug targets two proteins at once in early trial

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control

Last updated Jun 27, 2026 12:33 UTC

New hope for advanced cancer: experimental drug BHV-1530 enters first human tests

This early-stage trial tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disea…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control

Last updated Jun 27, 2026 12:33 UTC

New cancer drug TAK-505 enters first human trials

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control

Last updated Jun 27, 2026 12:32 UTC

Blood test guides chemo timing in head and neck cancer trial

This phase 2 study tests whether adding occasional chemotherapy to the immunotherapy drug pembrolizumab (Keytruda) can improve outcomes for people with recurrent or metastatic head and neck cancer. A blood test that measures tumor DNA helps doctors decide when to give the chemo. …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control

Last updated Jun 27, 2026 12:32 UTC

Experimental vaccine aims to boost immune attack on head and neck tumors

This phase 2 trial tests a new approach for patients with resectable head and neck squamous cell carcinoma. It combines an engineered mitochondrial vaccine (IMP3-Mito) with an immune checkpoint inhibitor (PD-1 inhibitor) given before and after surgery. The goal is to improve the …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control

Last updated Jun 27, 2026 12:31 UTC

New hope for advanced cancers: first human trial of ODM-212 begins

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control

Last updated Jun 27, 2026 12:31 UTC

Could a 3-Week radiation course replace 6 weeks for head and neck cancer?

This study compares a standard 6-week radiation course after surgery to a shorter 3-week course for people with head and neck cancer. The goal is to see if the shorter schedule works just as well at preventing cancer from coming back. About 369 participants will be randomly assig…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2, PHASE3 • Sponsor: All India Institute of Medical Sciences • Aim: Disease control

Last updated Jun 27, 2026 12:31 UTC

New hope for advanced cancer patients as experimental drug enters human testing.

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 12:31 UTC

New drug hopes to shrink Hard-to-Treat tumors

This early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:30 UTC

New drug duo targets Hard-to-Treat cancers

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control

Last updated Jun 27, 2026 12:29 UTC

Could less radiation be safer? new trial aims to cut side effects after head and neck cancer surgery

This phase II trial tests whether a personalized, reduced-volume radiation plan can safely lower side effects after surgery for head and neck cancer. About 50 patients will receive radiation only to high-risk areas, skipping some traditionally treated zones. The goal is to see if…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Olgun Elicin • Aim: Disease control

Last updated Jun 27, 2026 12:29 UTC

New combo treatment may spare head and neck cancer patients from disfiguring surgery

This study tests giving chemotherapy and immunotherapy before standard surgery for head and neck cancer. The goal is to shrink tumors enough so that surgeons can perform less extensive, function-preserving operations, reducing damage to swallowing, speech, and vision. The trial e…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC

New experimental drug CTX-8371 enters first human tests for tough cancers

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:09 UTC

New hope for head and neck cancer patients who Can't take chemo

This phase 3 trial tests a new treatment for people with high-risk head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. Participants receive radiation therapy combined with two drugs (nimotuzumab and benmelstobart) to see if this approach improves dis…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control

Last updated Jun 27, 2026 12:09 UTC

New Antibody-Drug conjugate KIVU-107 enters first human trials for Hard-to-Treat cancers

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:07 UTC

Could a Sugar-Blocking pill boost immunotherapy for tough cancers?

This phase 2 trial tests whether adding an experimental pill (GB1211) to the immunotherapy drug pembrolizumab (Keytruda) works better than Keytruda alone for people with advanced melanoma or head and neck cancer. The study will enroll 92 participants and measure how many patients…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

New cancer drug VIR-5525 enters first human trials for EGFR-Positive tumors

This early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

Radioactive seeds plus immunotherapy: a new hope for Hard-to-Treat head and neck cancer?

This trial is testing a new approach for people with head and neck cancer that has come back or spread and cannot be removed. It combines a device called DaRT, which is a tiny radioactive seed placed directly into the tumor, with the immunotherapy drug pembrolizumab (Keytruda). T…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

New CAR T-Cell therapy takes on Hard-to-Treat cancers

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

Experimental virus therapy takes on advanced cancers in first human trial

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

New antibody combo takes on Hard-to-Treat cancers

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Zumutor Biologics Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

Smart radiation: MRI helps target head and neck cancer, spare healthy tissue

This phase 2 trial is testing whether using MRI scans to adjust radiation therapy can better protect healthy organs in people with head and neck cancer. The study will enroll 35 patients who will receive standard intensity-modulated radiotherapy, but with a personalized boost gui…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control

Last updated Jun 27, 2026 12:02 UTC

Could a drug cocktail let head and neck cancer patients skip radiation?

This early-stage study is testing whether adding the immunotherapy drug cemiplimab to standard chemotherapy and cetuximab before surgery is safe for people with advanced head and neck cancer. The goal is to see if this combination can control the cancer well enough that patients …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 12:01 UTC

Can a targeted drug shrink tumors when immunotherapy fails?

This phase 2 trial is testing the drug cetuximab by itself in people with head and neck cancer that has come back or spread. Participants have already tried immunotherapy (PD-1 inhibitors) and it stopped working or caused side effects. The study will measure how many patients see…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control

Last updated Jun 27, 2026 11:03 UTC

Engineered immune cells take on Hard-to-Treat cancers

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control

Last updated Jun 27, 2026 11:03 UTC

New cancer drug CHS-114 enters first human tests

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control

Last updated Jun 27, 2026 11:03 UTC

Experimental cocktail aims to tackle recurrent head and neck cancer

This early-phase trial tests a combination of two newer drugs (tislelizumab and pamiparib) plus standard chemotherapy and re-radiation in 30 people whose head and neck cancer has come back. The main goal is to find a safe dose and check for side effects. Participants will be foll…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control

Last updated Jun 27, 2026 09:11 UTC

New drug combo shows promise against tough head and neck cancers

This study tests a new drug called volrustomig combined with standard chemotherapy (paclitaxel and carboplatin) in people with advanced head and neck cancer that is not caused by HPV. The goal is to see if this combination shrinks tumors before further treatment is tailored based…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control

Last updated Jun 27, 2026 09:11 UTC

New pill takes on brain tumors and metastases in early trial

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control

Last updated Jun 27, 2026 09:09 UTC

New drug cocktail aims to shrink head and neck tumors before surgery

This phase 2 trial is testing whether giving two drugs—pembrolizumab (Keytruda) and IO102-103—before surgery is safe and effective for people with head and neck cancer. The study will enroll 30 adults whose cancer can be surgically removed. Researchers will watch for side effects…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated Jun 27, 2026 09:09 UTC

Triple threat: immunotherapy plus chemo and radiation takes on head and neck cancer

This phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiotherapy can improve outcomes for people with locally advanced head and neck cancer. The study will enroll 27 participants and track how many remain cancer-free aft…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control

Last updated Jun 27, 2026 09:09 UTC

Could less radiation be enough for head and neck cancer?

This study tests whether giving lower doses of radiation to certain head and neck cancer patients can still effectively treat the cancer while causing fewer side effects. Participants receive chemotherapy and radiation, and doctors use a special PET scan to decide who can get the…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 09:09 UTC

Engineered immune cells take on recurrent head and neck cancer

This study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to fin…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 09:07 UTC

New immune drug targets common cancer mutation in early trial

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 09:04 UTC

New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 09:03 UTC

New combo attack: virus and supercharged immune cells take on Hard-to-Treat cancers

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to help the immune system attack cancer, followed by a…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control

Last updated Jun 27, 2026 09:02 UTC

New radioactive drug targets Hard-to-Treat cancers in early trial

This early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Karolinska University Hospital • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

New drug BL-B01D1 targets Hard-to-Treat cancers in early trial

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

New drug duo takes on tough head and neck cancer

This Phase 2 trial is testing whether a combination of two drugs, SYS6010 and Enlonstobart, can shrink tumors or slow the growth of head and neck cancer that has come back or spread. About 70 adults aged 18-75 who have not had prior systemic treatment for their advanced cancer wi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:14 UTC

New cancer drug SIM0610 enters first human tests

This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:13 UTC

New antibody targets FGFR1 to fight metastatic cancers

This study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The go…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Kidney Cancer Research Bureau • Aim: Disease control

Last updated Jun 27, 2026 08:13 UTC

New drug cocktail aims to fight recurrent head and neck cancer

This Phase II trial is testing whether two experimental drugs (SI-B001 and SI-B003) plus standard chemotherapy can help people with head and neck cancer that has come back or spread. About 60 adults aged 18 to 75 will receive the combination as their first treatment. The main goa…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:13 UTC

New drug duo targets Hard-to-Treat head and neck cancer

This phase II trial tests a new drug called SIBP-03, given together with cetuximab, for people with advanced head and neck cancer that has returned or spread. The study will enroll 81 adults who have already tried immunotherapy and platinum chemotherapy. The goal is to see if the…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control

Last updated Jun 27, 2026 08:11 UTC

GPS for surgeons: new navigation tool aims to improve head and neck cancer outcomes

This study tests a navigation system that helps surgeons remove head and neck tumors more precisely. During surgery, the system creates a 3D map of the tumor and its edges, which is then used to plan follow-up radiation therapy. The goal is to reduce the chance of leftover cancer…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Juergen Debus • Aim: Disease control

Last updated Jun 27, 2026 08:10 UTC

New drug SIBP-A13 enters human testing for hard-to-treat cancers

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants will re…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control

Last updated Jun 27, 2026 08:09 UTC

Radioactive injection targets Hard-to-Treat cancers in early trial

This early-phase study tests a radioactive drug called lutetium BL-ARC001 in 22 people with advanced lung, breast, head and neck, or other solid tumors that have stopped responding to standard therapies. The drug is given by IV infusion over a 6-week cycle. The main goals are to …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:08 UTC

New antibody drug takes on Hard-to-Treat cancers

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Dren Bio • Aim: Disease control

Last updated Jun 27, 2026 08:08 UTC

New drug trial offers hope for Hard-to-Treat head and neck cancers

This early-phase study tests a new drug called BL-M24D1 in people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 16 adults aged 18 to 75 will ta…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:07 UTC

New Tumor-Injected drug shows promise in early cancer trial

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: OncoNano Medicine, Inc. • Aim: Disease control

Last updated Jun 27, 2026 08:06 UTC

New program aims to speed up radiation for head and neck cancer patients

This trial tests a program called ENDURE that helps head and neck cancer patients start radiation therapy within 6 weeks after surgery. The program provides education, social support, and better coordination among doctors. Researchers will compare it to usual care in 532 adults w…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Medical University of South Carolina • Aim: Disease control

Last updated Jun 27, 2026 08:03 UTC

New pill shows promise for Hard-to-Treat cancers

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control

Last updated Jun 27, 2026 08:03 UTC

New virus therapy takes on advanced cancers in first human trial

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 08:01 UTC

New pill takes on tough cancers: early trial launches

This study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:56 UTC

New drug duo aims to shrink head and neck tumors

This study tests whether a combination of two drugs, ACR-368 and low-dose gemcitabine, can shrink tumors or slow cancer growth in people with head and neck cancer that has come back or spread. About 43 adults will receive the drugs every two weeks. The goal is to see if the treat…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control

Last updated Jun 27, 2026 07:55 UTC

New smart drug takes aim at Hard-to-Treat cancers

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:54 UTC

Glow-in-the-Dark dye could help surgeons see hidden cancer during surgery

This early-stage trial is testing whether a combination of two imaging agents can help surgeons better detect and remove head and neck cancer. One agent uses a radioactive label for pre-surgery scans, and the other uses a fluorescent dye that makes cancer cells glow during surger…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 07:53 UTC

New drug duo takes on hard-to-treat head and neck cancers

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together, in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 who have tried at…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

Could less radiation be enough for HPV-Positive throat cancer?

This study is testing whether a lower dose of radiation after surgery can safely treat HPV-positive head and neck cancer while reducing long-term side effects. About 304 participants will receive either standard or reduced radiation, with or without chemotherapy. The goal is to s…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Technische Universität Dresden • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

Experimental triple therapy takes on Hard-to-Treat Head-Neck cancer

This early-phase trial is testing a new drug called RiMO-301, given as an injection directly into the tumor, along with radiation therapy and an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination is safe and can shrink tumors in people with advanced hea…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 26, 2026 17:45 UTC

New skin flap could reduce surgery side effects for head and neck cancer patients

This study tests a new surgical technique using a thin skin flap from the groin area to rebuild the mouth or throat after cancer removal. The goal is to see if it causes fewer problems at the donor site compared to standard flaps. Forty adults with head and neck cancer will be fo…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Disease control

Last updated Jun 26, 2026 17:27 UTC

New Dual-Target antibody enters human trials for advanced cancers

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control

Last updated Jun 26, 2026 15:48 UTC

New cancer drug NX-1607 enters first human trials

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control

Last updated Jun 26, 2026 14:25 UTC

New PET tracer could slash unnecessary biopsies for head and neck cancer patients

This early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, which is designed to make head and neck squamous cell carcinoma show up more clearly on PET/CT scans. About 25 adults with suspicious or unclear findings on standard scans will receive the tracer and b…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 27, 2026 12:32 UTC

New scan could spot hidden cancer spread in head and neck patients

This study tests a new imaging agent called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new agent and th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis

Last updated Jun 27, 2026 12:31 UTC

Glow stick for cancer: new dye helps surgeons spot hidden tumors

This study tests a dye called pegsitacianine that makes cancer cells glow during surgery. It is for 120 adults with head and neck cancer, including those with an unknown primary tumor. The goal is to see if the dye helps surgeons find and remove all cancer tissue safely.

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis

Last updated Jun 27, 2026 12:08 UTC

New imaging agent aims to spot hidden cancer in neck lymph nodes

This early-stage trial tests whether a radioactive imaging agent called 111In-panitumumab can help find cancer that has spread to lymph nodes in people with head and neck cancer. The agent binds to a protein common on cancer cells and lights up on a special scan. About 30 partici…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 27, 2026 09:11 UTC

New scan could sharpen view of head and neck cancers

This early-phase study tests whether a special tracer called 89Zr panitumumab, used with PET/MRI scans, can show head and neck tumors more clearly than the standard FDG tracer. Fourteen newly diagnosed patients scheduled for surgery will receive both scans. The results are for re…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Diagnosis

Last updated Jun 27, 2026 08:07 UTC

New imaging agent aims to spot tumors and track immunotherapy

Prevention Recruiting now

This early-phase trial is testing a new imaging agent (GEH200520/GEH200521) that lights up on PET scans to help see solid tumors. In Part A, 50 adults with advanced solid tumors will receive the agent and have scans to check safety and how the agent spreads in the body. Part B wi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: GE Healthcare • Aim: Diagnosis

Last updated Jun 27, 2026 07:58 UTC

Ice microneedles aim to stop radiation skin damage in cancer patients

This early-stage study tests whether a protein called CFH, delivered through tiny ice microneedles, can prevent skin scarring caused by radiation therapy. Nine adults with head and neck cancer who will receive radiation after surgery are being enrolled. The main goals are to chec…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: West China Hospital • Aim: Prevention

Last updated Jun 27, 2026 12:31 UTC

New cream may stop radiation burns in cancer patients

Prevention Recruiting now

This study tests a new cream made from amino acids to prevent skin damage caused by radiation therapy in people with head and neck cancer. About 40 participants will use the cream during their radiation treatment. The goal is to see if it reduces skin redness, pain, and treatment…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: West China Hospital • Aim: Prevention

Last updated Jun 27, 2026 12:08 UTC

New drug aims to ease painful mouth sores for head and neck cancer patients

This phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief

Last updated Jun 27, 2026 14:02 UTC

Can pre-treatment nutrition and exercise ease head and neck cancer therapy?

This study looks at whether offering nutritional counseling and exercise programs before and during radiation or chemoradiation is helpful for head and neck cancer patients. Researchers want to see if patients are willing to join and attend these sessions. The goal is to improve …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: University of Miami • Aim: Symptom relief

Last updated Jun 27, 2026 14:00 UTC

Can a constipation drug help head and neck cancer patients before surgery?

This study tests whether a drug called methylnaltrexone is safe for people with head and neck cancer when taken for two weeks before their surgery. The drug is already used for constipation, but researchers want to see if it can be given safely in this setting. About 25 adults wi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Jun 27, 2026 13:07 UTC

Can a fat flap reduce neck pain after cancer? small study aims to find out

This pilot study tests whether a buried free fat flap surgery can safely reduce neck problems like pain, stiffness, and swallowing trouble in people treated for head and neck cancer. Twelve adults who need a salvage neck dissection will receive the fat flap procedure. Researchers…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief

Last updated Jun 27, 2026 13:00 UTC

New radiation approach aims to cut painful side effects in head and neck cancer

This study tests if proton radiation causes fewer side effects than standard photon radiation in people with head and neck cancer. About 400 adults aged 40 and older will receive either proton or photon therapy, plus possible chemotherapy. The main goal is to see if protons reduc…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Oslo University Hospital • Aim: Symptom relief

Last updated Jun 27, 2026 12:34 UTC

New hope for cancer patients: drug may replace opioids for mouth sore pain

This study tests whether a high dose of gabapentin, a non-opioid pain medicine, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 participants will be randomly assigned to rec…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief

Last updated Jun 27, 2026 12:32 UTC

Smart patch could spot chemo side effects before they become dangerous

This trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief

Last updated Jun 27, 2026 12:31 UTC

Jelly supplement aims to ease chemo side effects in cancer patients

This study is testing a jelly-based nutritional supplement in 52 people with head and neck, lung, or rectal cancer who are receiving standard cancer treatments like chemo or radiation. The supplement contains ingredients like arginine, omega-3, and olive oil, and is taken twice d…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Symptom relief

Last updated Jun 27, 2026 12:04 UTC

Smart radiotherapy aims to cut cancer treatment side effects

This study tests a new way to give radiation for head and neck cancer. Instead of a fixed plan, the radiation is adjusted daily to match changes in the patient's body. The goal is to lower side effects like trouble swallowing and dry mouth. About 40 adults with throat or voice-bo…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief

Last updated Jun 27, 2026 12:03 UTC

New radiation approach aims to ease head and neck cancer pain in fewer sessions

This phase 2 trial tests whether a modern radiation technique called stereotactic body radiotherapy (SBRT) can safely deliver a strong dose of radiation in just 3 to 5 sessions to relieve symptoms from head and neck cancer. The study involves 108 adults whose cancer cannot be cur…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Jun 27, 2026 09:06 UTC

Could a common drug help cancer patients keep their appetite?

This phase 2 trial tests whether adding olanzapine to standard care helps manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults will receive either olanzapine plus standard symptom management or standard care alone. The main goal is to s…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief

Last updated Jun 27, 2026 09:05 UTC

Heavy lifting may help cancer survivors rebuild strength

This study tests whether a heavy lifting strength training program is safe and helpful for people who have finished treatment for head and neck cancer at least one year ago. Researchers want to see if it improves muscle strength, physical function, fatigue, and quality of life co…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Alberta • Aim: Symptom relief

Last updated Jun 27, 2026 09:03 UTC

New study tests whether coaching speeds up cancer care for rural patients

This study tests a program called CARES that provides nurse navigators and counselors to rural cancer patients. The goal is to see if this support helps patients start and finish treatment more quickly and improves their quality of care. About 320 adults with solid tumors like lu…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: University of Colorado, Denver • Aim: Symptom relief

Last updated Jun 27, 2026 09:02 UTC

Caregiver training may ease burden after head and neck cancer surgery

This study tests whether special training for caregivers of head and neck cancer patients can reduce the stress of caregiving and help patients recover better at home. About 76 caregivers will be split into two groups: one gets standard care, the other gets hands-on training from…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Symptom relief

Last updated Jun 27, 2026 08:08 UTC

Heat boost: new combo therapy aims to shrink incurable tumors

This study tests whether adding a special heat treatment (water-filtered infrared, or wIRA) to standard palliative radiation can help shrink tumors and ease symptoms in people with advanced head, neck, or skin cancer that cannot be cured. About 60 adults will receive the combined…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: King's College London • Aim: Symptom relief

Last updated Jun 27, 2026 08:05 UTC

500 cancer patients join quest to unlock hidden clues in their blood and tumors

This study enrolls 500 adults with advanced head and neck cancer who are starting standard immunotherapy. Researchers will collect blood and tumor samples over time to look for genetic and immune markers that may predict how well treatment works or why it stops working. The goal …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Tempus AI • Aim: Knowledge-focused

Last updated Jun 27, 2026 13:07 UTC

Fiber fix: could a High-Fiber diet protect cancer patients from muscle loss?

This study looks at whether eating more fiber can help head and neck cancer patients avoid muscle loss (sarcopenia). Researchers will track 59 adults from diagnosis for six months, measuring their fiber intake, muscle mass, and inflammation. The goal is to understand the link bet…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: University of Oklahoma • Aim: Knowledge-focused

Last updated Jun 27, 2026 13:01 UTC

Blood test may predict throat cancer comeback

This study looks at 220 people with HPV-related oropharynx cancer to see if certain gene mutations (TRAF3 and CYLD) and levels of HPV DNA in the blood can predict if the cancer will come back after treatment. Participants give blood samples and fill out quality-of-life questionna…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:24 UTC

Remote hearing tests could save cancer Patients' hearing

This study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:23 UTC

Scientists hunt for genetic clues in head and neck cancers

This study looks at the genetic makeup of head and neck tumors from 1,000 people to find markers that predict how well a patient will respond to treatment and their chances of survival. Researchers will also search for new diagnostic markers. The goal is to better understand why …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Montefiore Medical Center • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:05 UTC

Cancer Patients' nutrition under the microscope: study tracks body changes during treatment

This study follows 110 adults with head and neck, lung, or rectal cancer to see how their nutrition and body composition change during standard cancer treatments. Researchers will measure food intake, muscle mass, and strength over time. The goal is to gather data that could late…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:04 UTC

New tool aims to predict cancer treatment toxicity in older patients

This study is testing a new tool designed to predict side effects from cancer treatment in elderly patients (70+) with advanced head and neck cancer. The goal is to see if the tool can help doctors choose safer treatments. Only 3 participants are being enrolled, making this a ver…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: European Institute of Oncology • Aim: Knowledge-focused

Last updated Jun 27, 2026 12:00 UTC

Can MRI make cancer radiation smarter? new study investigates

This study is testing whether repeated MRI scans during radiation therapy for head and neck cancer can help doctors see how the tumor is responding. About 173 people with newly diagnosed head and neck cancer will get extra MRI scans during their standard treatment. The goal is to…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused

Last updated Jun 27, 2026 09:11 UTC

Virtual reality could make head and neck cancer surgery more precise

This study explores whether virtual reality and 3D models can help surgeons plan head and neck cancer operations more accurately. About 160 adults with head and neck cancer will take part. The goal is to see if this technology reduces the chance of leftover cancer cells and impro…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Thomas Jefferson University • Aim: Knowledge-focused

Last updated Jun 27, 2026 09:05 UTC

New study tracks outcomes of Second-Chance surgery for head and neck cancer

The RESCUE study is looking at 400 adults who have salvage surgery for head and neck cancer that came back after radiation. Researchers will track how long patients live without the cancer returning and how well they function after surgery. They will also analyze tumor tissue, bl…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused

Last updated Jun 27, 2026 09:05 UTC

Scientists probe cancer's secret evolution after radiation

This study looks at how head and neck cancer cells change after radiation treatment. Researchers will collect tissue and blood samples from 20 adults who had radiation before and are now having robotic surgery for new or returning tumors. The goal is to understand why some cancer…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused

Last updated Jun 27, 2026 09:04 UTC

New antibody fragments light up tumors in early imaging trial

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Var2 Pharmaceuticals • Aim: Knowledge-focused

Last updated Jun 27, 2026 08:07 UTC

Blood test may spare throat cancer patients from radiation side effects

This study is for people with HPV-related throat cancer who have surgery to remove their tumor. Researchers are testing whether a blood test that looks for leftover tumor DNA can safely identify patients who do not need additional radiation. The goal is to reduce side effects by …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused

Last updated Jun 27, 2026 07:56 UTC

New imaging study aims to spot radiation damage to neck arteries

This study looks at how radiation therapy for head and neck cancers affects the blood vessels in the neck. Researchers will use two types of PET/CT scans to compare images taken before and after treatment. The goal is to better understand and detect radiation-related vascular dam…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused

Last updated Jun 27, 2026 07:55 UTC

Can a 'Mini Tumor' in a dish predict your best cancer drug?